Compared to the WHO classification of 2016, AML with myelodysplasia-related changes (AML-MRC), the most common subtype in older patients, is now called AML myelodysplasia-related (AML-MR) in WHO 2022 and is split up into AML with myelodysplasia-related gene mutations (AML-MR-M), AML with myelodysplasia-related cytogenetic abnormalities (AML-MR-C) and AML with mutated TP53 [2–4] in ICC 2022. This evidence concerns the gene TP53 and acute myeloid leukemia.